Latest Astellas Pharma Inc (ALPMY) Headlines Was

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Astellas Pharma Inc (ALPMY) Headlines

Was Medivation's Quarter a Disaster?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 03, 5:30PM CST
Medivation's  sell-off last week reflects investor disappointment in guidance for sales of Xtandi, a prostate cancer drug prescribed to patients who fail to respond to chemotherapy. Sales of Xtandi jumped double digit percentages...

Medivation Swings to Earnings in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:30AM CST
Xtandi's approval in the pre-chemo setting would boost sales significantly.

Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.

Primco Files Preliminary Form 14c to Increase Authorized Shares
PR Newswire - Tue Feb 18, 11:30PM CST
Primco Management Inc. (OTCQB: PMCM), a fully integrated multi-media entertainment and real estate development company today announced that the Company has filed Form 14c, as required by the Securities and Exchange Commission, informing shareholders of an increase in the authorized to 25 billion common shares as a reserve requirement for possible future conversion issuances, in accordance with contractual obligations to convertible debt holders based on the recent low stock price of $0.0001. The increase will further allow Primco to have sufficient shares available for equity funding, and/or for potential acquisitions which the Board of Directors may determine is in the best interest of the shareholders.

AVEO/Astellas Terminate Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 3:30PM CST
AVEO Pharma and Astellas announced their decision to terminate their agreement for the development and commercialization of tivozanib.

Vical Q4 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 11:10AM CST
Vical's fourth quarter loss narrows

Announcement of Intention to Privatize and Invitation to Express Interest
PR Newswire - Thu Feb 13, 4:31AM CST
The Government of the Republic of Chad formally announces its intention to partially privatize the Société des Télécommunications du Tchad ("Groupe SOTEL Tchad") pursuant to the terms of law 004/PR/96. The Ministry of Commerce and Industry hereby invites interested parties to express interest to acquire a majority of the shares of SOTEL

Cytokinetics Rises on Q4 Earnings Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 10:00AM CST
Cytokinetics reported fourth quarter 2013 earnings of 21 cents.

AVEO/Astellas Terminate Tivozanib Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 4:10PM CST
AVEO Pharmaceuticals and partner Astellas Pharma announced their decision to discontinue a phase II study evaluating tivozanib in patients suffering from locally recurrent or metastatic triple negative breast cancer.

Medivation Prevails in PREVAIL Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 29, 12:50PM CST
Medivation and Astellas intend to file for regulatory approval for the pre-chemo population shortly.

Early 2014 Advancing Companies with Expansion & New Distribution Opportunities: RiceBran, Whole Foods, Hain Celestial, DryShips and Chelsea Therapeutics
PR Newswire - Thu Jan 16, 8:05AM CST
News updates for NASDAQ companies making strides with financial results, new agreements & distribution opportunities: RiceBran Technologies (NASDAQ: RIBT), Whole Foods Market Inc. (NASDAQ: WFM), The Hain Celestial Group, Inc. (NASDAQ: HAIN), DryShips, Inc. (NASDAQ: DRYS) and Chelsea Therapeutics International Ltd. (NASDAQ: CHTP)

AVEO Falls on Tivozanib News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 4:20PM CST
AVEO Pharmaceuticals announced that data from a planned interim analysis of the phase II BATON study on tivozanib showed that the study is unlikely to meet the primary endpoint.

3 Investing Lessons From Dendreon
Leo Sun, The Motley Fool - Motley Fool - Wed Dec 04, 3:41PM CST
The fall of Dendreon is a grim cautionary tale for biotech investors. The stock has fallen more than 40% year to date, and is down more than 90% since its peak in 2010. Wall Street had believed that Dendreon's only marketed...

Medivation Q3 Loss Narrower Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 13, 7:10AM CST
Xtandi U.S. net sales are expected to surpass the earlier guidance of $345-$365 million.

AVEO Q3 Loss Wider than Expected, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 12, 7:30AM CST
AVEO Pharmaceuticals reported third quarter 2013 loss of 47 cents per share.

Medivation Soars on Positive Xtandi Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 23, 3:00PM CDT
Medivation's share price shot up 8.2% on Oct 22, 2013 to close the trading session at $53.89.

Can an EU Approval Save This Dying Biotech?
Leo Sun, The Motley Fool - Motley Fool - Thu Sep 19, 9:29AM CDT
Dendreon is one of the most well-known cautionary tales of hype and broken promises in the biotech industry. In April 2010, the stock hit an all-time high of $54 per share after the company's prostate cancer drug Provenge was approved by the Food...

Astellas to Host Executive Women's Day at 2013 TOUR Championship by Coca-Cola
PR Newswire - Tue Sep 17, 6:30AM CDT
The PGA TOUR and Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), will host their 17th Astellas Presents Executive Women's Day, a day-long forum focusing on professional, health-related and personal development discussions, at the 2013 TOUR Championship by Coca-Cola in Atlanta. The event is part of the PGA TOUR's Women's Initiative and is the final Executive Women's Day program in the 2013 season.

Humana Downgraded to Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 05, 4:05PM CDT
On Sep 4, 2013, we downgraded our recommendation on Humana Inc. to Neutral from Outperform.

Astellas and Merck Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 04, 4:00PM CDT
Astellas Pharma joined forces with Merck for the co-promotion of its SGLT2 inhibitor, ipragliflozin (ASP1941)

Astellas Pharma Inc (ALPMY) Stock Research Links

ALPMY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 26

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 68

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading
LRM Adds Two IND Studies Testing Injectable PDGF in Skin

Updated Category News Views 9

Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 39

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 35

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 182

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 148

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 32

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation into GoHealth, Inc. Sparks Investor Concerns

Updated Category News Views 354

GoHealth, Inc. Under Investigation for Alleged Securities Fraud Pomerantz LLP has initiated an investigation regarding potential claims involving investors of GoHealth, Inc. (NASDAQ: GOCO). This probe aims to determine whether the company and some of its executives have participated in misleading practices concerning their financial statements. The firm is reaching out to...

Continue Reading
Exploring the Features of the 2026 Toyota GR Corolla

Updated Category News Views 334

Unleashing the Adventure with the 2026 Toyota GR Corolla Get ready for an adventurous experience with the all-new 2026 Toyota GR Corolla. Engineered to perfection, this vehicle is equipped with the innovative GR-FOUR All-Wheel Drive System, making it a formidable companion whether you're racing on the track or maneuvering through rugged terrains. The GR Corolla is...

Continue Reading
Tandem Diabetes Care Boosts Sales Guidance After Q3 Success

Updated Category News Views 65

Tandem Diabetes Care Reports Impressive Q3 Financial Results Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading name in insulin delivery and diabetes management technology, has reported its financial accomplishments for the third quarter of 2024. Following an exceptional performance, the company has also increased its sales guidance for the upcoming fiscal year. Key...

Continue Reading
Green IT Services Growth: A Comprehensive Market Overview

Updated Category News Views 193

Green IT Services Market: A Dynamic Overview The evolution of technology is more than just a trend; it represents a paradigm shift towards sustainability. As organizations embrace digital transformation, the focus on Green IT services has rapidly gained importance. The latest analyses indicate that the Green IT Services market, valued at USD 18.8 billion in recent years,...

Continue Reading
Duke Energy's Response to Hurricane Helene's Aftermath

Updated Category News Views 558

Hurricane Helene Aftermath and Power Restoration Efforts Following the severe impact of Hurricane Helene, Duke Energy (NYSE: DUK) has made remarkable progress in restoring electrical services to over 2.16 million customers. Despite these extensive restoration efforts, around 334,000 customers are still without power, largely in Upstate South Carolina and the mountainous...

Continue Reading